Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Jennings

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Plos One|November 22, 2013
Bacterially produced recombinant influenza vaccines based on virus-like particlesAndrea Jegerlehner, Franziska Zabel, Alice Langer, et al.
Vaccine|March 2, 2010
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in miceYu Zou, Ivo Sonderegger, Gerd Lipowsky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particlesGunther Spohn, Katrin Schwarz, Patrik Maurer, et al.
European Journal of Immunology|October 19, 2006
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitisTill A Röhn, Gary T Jennings, Marcela Hernandez, et al.
Intervirology|February 5, 2003
Virus-like particles as a modular system for novel vaccinesFranziska Lechner, Andrea Jegerlehner, Alain C Tissot, et al.
Virology Journal|July 8, 2010
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in miceGunther Spohn, Gary T Jennings, Byron Ee Martina, et al.
European Journal of Immunology|June 23, 2005
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicityPatrik Maurer, Gary T Jennings, Jörg Willers, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetesGunther Spohn, Christian Schori, Iris Keller, et al.
Plos One|March 31, 2010
Versatile virus-like particle carrier for epitope based vaccinesAlain C Tissot, Regina Renhofa, Nicole Schmitz, et al.
The Journal of Allergy and Clinical Immunology|June 6, 2006
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adultsThomas M Kündig, Gabriela Senti, Gabriel Schnetzler, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Plos One|November 22, 2013
Bacterially produced recombinant influenza vaccines based on virus-like particlesAndrea Jegerlehner, Franziska Zabel, Alice Langer, et al.
Vaccine|March 2, 2010
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in miceYu Zou, Ivo Sonderegger, Gerd Lipowsky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particlesGunther Spohn, Katrin Schwarz, Patrik Maurer, et al.
European Journal of Immunology|October 19, 2006
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitisTill A Röhn, Gary T Jennings, Marcela Hernandez, et al.
Intervirology|February 5, 2003
Virus-like particles as a modular system for novel vaccinesFranziska Lechner, Andrea Jegerlehner, Alain C Tissot, et al.
Virology Journal|July 8, 2010
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in miceGunther Spohn, Gary T Jennings, Byron Ee Martina, et al.
European Journal of Immunology|June 23, 2005
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicityPatrik Maurer, Gary T Jennings, Jörg Willers, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetesGunther Spohn, Christian Schori, Iris Keller, et al.
Plos One|March 31, 2010
Versatile virus-like particle carrier for epitope based vaccinesAlain C Tissot, Regina Renhofa, Nicole Schmitz, et al.
The Journal of Allergy and Clinical Immunology|June 6, 2006
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adultsThomas M Kündig, Gabriela Senti, Gabriel Schnetzler, et al.
Pageof 4